05-11-2010: Epistem plc announced that it has been reappointed for up to five years to provide preclinical testing services as a subcontractor to the U.S. National Institutes of Health's (NIH) Radiation/Nuclear Medical Countermeasure Product Development Support Services Contract, which has been awarded to the University of Maryland School of Medicine (UMSOM) in Baltimore. In the first subcontract commencing in 2006, Epistem received approximately 3.5 million USD to develop models and evaluate novel drugs that can treat the effects of radiation damage to the gastrointestinal tract. The new five year subcontract is expected to extend and grow the scope of the collaborative relationship.
This UMSOM programme, referred to as the Medical Countermeasures against Radiological Threats (MCART) programme, is funded by the NIH's National Institute of Allergy and Infectious Diseases (NIAID), and aims to identify and develop new treatments for use in the event of a radiological or nuclear incident. As a subcontractor, Epistem is a member of the research consortium which has been awarded the contract and comprises radiobiology experts, each with specialist knowledge of the effects of radiation in different tissues of the body. Epistem's role is to provide specialized gastrointestinal models to assess the efficacy and mode of action of new drugs entering the programme. In the previous subcontract, the Company refined drug screening methods, further characterised the biology of radiation damage in the gastrointestinal tract and assessed several new drug candidates. Other members of the consortium, which is led by the UMSOM, include Indiana University School of Medicine and Duke University in the USA. Epistem is the only research facility outside of North America within the consortium.
Dr Catherine Booth, Managing Director and Co-Founder of Epistem commented, "The past few years collaboration with NIAID and the UMSOM have been incredibly successful. A series of models have been developed and used to screen potential treatments for acute radiation damage. This fresh contract covering five years will allow us to progress successful candidate drugs, in addition to developing models to assess treatments for the delayed effect of radiation damage".
The feared Legionella pneumophila bacteria is responsible for legionellosis, an infectious disease that can lead to pneumonia. In order to infect us, this pathogen has developed a complex method enabling it to camouflage itself and go unnoticed in our cells, thus avoiding these acting again ... more
For leading a study that was the first to define appropriate bone density screening intervals for older women, Margaret Gourlay, MD, MPH, of the University of North Carolina School of Medicine has been honored with a Top 10 Clinical Research Achievement Award from the Clinical Research Foru ... more
Stem cells and tissue-specific cells can be grown in abundance from mature mammalian cells simply by blocking a certain membrane protein, according to scientists at the University of Pittsburgh School of Medicine and the National Institutes of Health (NIH). Their experiments, reported today ... more
The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency—making important medical discoveries that improve health and save lives.
Epistem Plc announced a three year biomarker collaboration with GlaxoSmithKline in the field of fibrosis research. The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp(TM) technology to facilitate bu ... more
Epistem plc announce a partnership with Dr Matthew Hardman at The University of Manchester in which novel preclinical models for cutaneous wound healing, developed within Dr Hardman’s laboratory, will be transferred to Epistem.Epistem and The University of Manchester have been awarded a Kno ... more
Epistem announced the formation of a human DNA Identification collaboration with the National Policing Improvement Agency (NPIA). Epistem and the NPIA will be evaluating Epistem’s Genedrive™ molecular device as part of the NPIA’s ADAPT programme (Accelerated DNA Profiling Technology program ... more